![]() FR is an NC3Rs board member and has shareholdings in GSK. OHP is vice president of Academia Europaea, editor in chief of Function, senior executive editor of the Journal of Physiology, and member of the Board of the European Commission’s SAPEA (Science Advice for Policy by European Academies). NPdS and TS are associate editors of BMJ Open Science. MM is a member of the Animals in Science Committee and on the steering group of the UK Reproducibility Network. UD, MM, NPdS, CJM, ESS, TS, and HW are members of EQIPD. CJM has shareholdings in Hindawi, is on the publishing board of the Royal Society, and on the EU Open Science policy platform. SEL and UD are on the advisory board of the UK Reproducibility Network. VH, KL, EJP, and NPdS are NC3Rs staff role includes promoting the ARRIVE guidelines. STH is chair of the NC3Rs board trusteeship of the BLF, Kennedy Trust, DSRU, and CRUK member of Governing Board, Nuffield Council of Bioethics, member Science Panel for Health (EU H2020) founder and NEB Director Synairgen consultant Novartis, Teva, and AZ and chair MRC/GSK EMINENT Collaboration. ![]() ME, MM, and ESS have received funding from NC3Rs. AC, CJM, MM, and ESS were involved in the IICARus trial. WJB serves on the Independent Statistical Standing Committee of the funder CHDI foundation. WJB, ICC, and ME are authors of the original ARRIVE guidelines. NPdS, KL, VH, and EJP are employees of the NC3Rs.Ĭompeting interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: AA is the editor in chief of the British Journal of Pharmacology. The work is made available under the Creative Commons CC0 public domain dedication.įunding: This work was supported by the National Centre of the Replacement, Refinement & Reduction on Animals in Research (NC3Rs, ). This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. PLoS Biol 18(7):Īcademic Editor: Isabelle Boutron, University Paris Descartes, FRANCE (2020) Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0. This document also covers advice and best practice in the design and conduct of animal studies to support researchers in improving standards from the start of the experimental design process through to publication.Ĭitation: Percie du Sert N, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, et al. It provides further information about each of the 21 items in ARRIVE 2.0, including the rationale and supporting evidence for their inclusion in the guidelines, elaboration of details to report, and examples of good reporting from the published literature. This explanation and elaboration document was developed as part of the revision. The revised guidelines are published alongside this paper. We have revised the ARRIVE guidelines to update them and facilitate their use in practice. Despite widespread endorsement by the scientific community, the impact of ARRIVE on the transparency of reporting in animal research publications has been limited. The ARRIVE guidelines (Animal Research: Reporting In Vivo Experiments) were developed in 2010 to help authors and journals identify the minimum information necessary to report in publications describing in vivo experiments. Transparent and accurate reporting is vital to this process it allows readers to assess the reliability of the findings and repeat or build upon the work of other researchers. Improving the reproducibility of biomedical research is a major challenge.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |